Enhancement of pharmacokinetic properties and in vivo efficacy of benzylidene ketal M(2) muscarinic receptor antagonists via benzamide modification.

[1]  R. Brinton,et al.  Advances and Challenges in the Prevention and Treatment of Alzheimer's Disease , 1998, Pharmaceutical Research.

[2]  J. Lachowicz,et al.  Synthesis and structure-activity relationships of M(2)-selective muscarinic receptor ligands in the 1-[4-(4-arylsulfonyl)-phenylmethyl]-4-(4-piperidinyl)-piperazine family. , 2002, Bioorganic & medicinal chemistry letters.

[3]  W. Greenlee,et al.  Metabolic stabilization of benzylidene ketal M(2) muscarinic receptor antagonists via halonaphthoic acid substitution. , 2001, Bioorganic & medicinal chemistry letters.

[4]  C. Strader,et al.  Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. , 2001, Farmaco.

[5]  J. Lachowicz,et al.  Benzylidene ketal derivatives as M2 muscarinic receptor antagonists. , 2000, Bioorganic & medicinal chemistry letters.

[6]  F. Bymaster,et al.  Therapeutic opportunities for muscarinic receptors in the central nervous system. , 2000, Journal of medicinal chemistry.

[7]  L. Fernández-Novoa,et al.  Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. , 2000, Drugs of today.

[8]  Clader Jw.  Recent advances in cholinergic drugs for Alzheimer's disease. , 1999 .

[9]  Walter A. Korfmacher,et al.  Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats , 1999 .

[10]  D. Doller,et al.  Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. , 1999, Bioorganic & medicinal chemistry letters.

[11]  M. Kistler,et al.  Cholinergic improvement of a naturally-occurring memory deficit in the young rat , 1996, Brain Research.

[12]  R. Mcquade,et al.  Identification of the primary muscarinic autoreceptor subtype in rat striatum as m2 through a correlation of in vivo microdialysis and in vitro receptor binding data. , 1995, The Journal of pharmacology and experimental therapeutics.

[13]  H. Doods.  Lipophilic muscarinic M2 antagonists as potential drugs for cognitive disorders , 1995 .

[14]  A. Kozikowski,et al.  Alzheimer's therapy: an approach to novel muscarinic ligands based upon the naturally occurring alkaloid himbacine. , 1992 .

[15]  J. Saunders,et al.  Chapter 4. Central Muscarinic Ligands and Receptors , 1989 .

[16]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[17]  S. Hecht,et al.  Evidence for Metabolic α Hydroxylation of N -Nitrosopyrrolidine , 1978 .